450 Participants Needed

Percutaneous vs Surgical Repair for Mitral Valve Regurgitation

(PRIMARY Trial)

Recruiting at 45 trial locations
CP
EM
Overseen ByEllen Moquete, RN
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV) transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S., Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all devices legally marketed for TEER of primary degenerative MR in a particular country are eligible to be used in this trial.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your healthcare provider.

Is transcatheter edge-to-edge repair (TEER) for mitral valve regurgitation safe?

TEER, including the MitraClip system, is generally considered safe for treating mitral valve regurgitation, with studies showing it as a less invasive option for patients. However, there may be a need for further surgical intervention in some cases, and safety data is still being gathered.12345

How is the Mitral valve TEER treatment different from other treatments for mitral valve regurgitation?

Mitral valve TEER (Transcatheter Edge-to-Edge Repair) is unique because it is a less invasive procedure compared to traditional open-heart surgery, making it suitable for patients who are at high risk for surgical complications. It involves using a device like the MitraClip to repair the valve through a catheter, which is inserted through a small incision, reducing recovery time and hospital stay.12346

What data supports the effectiveness of this treatment for mitral valve regurgitation?

Research shows that transcatheter edge-to-edge repair (TEER) is an effective treatment for mitral valve regurgitation, providing symptom relief and improved outcomes, especially for patients who are not suitable for open heart surgery.12478

Who Is on the Research Team?

ML

Martin Leon, MD

Principal Investigator

Columbia University

PO

Patrick O'Gara, MD

Principal Investigator

Brigham and Women's Hospital

JC

Joann Chikwe, MD

Principal Investigator

Cedars Sinai

Are You a Good Fit for This Trial?

This trial is for adults aged 65 or older with a specific heart valve condition called primary degenerative mitral regurgitation. Candidates must be able to perform physical tests and complete health questionnaires, and are eligible across all surgical risk levels. Exclusions include recent febrile illness, need for other heart surgeries, certain allergic reactions, bleeding disorders, prior mitral interventions, and severe co-existing conditions.

Inclusion Criteria

If you have atrial fibrillation and need both catheter-based and surgical ablation, your local heart team must confirm that you are eligible for both procedures.
I am 65 or older with severe valve leakage as shown by an echo test.
My heart condition is considered low, intermediate, or high risk by my medical team.
See 2 more

Exclusion Criteria

You might not be able to keep up with the required check-ups and appointments.
I have a thickened heart muscle that obstructs blood flow.
You have secondary or functional mitral regurgitation.
See 17 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo either mitral valve transcatheter edge-to-edge repair (TEER) or surgical repair

1 month
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

5 years
Annual visits (in-person)

Long-term follow-up

Participants are followed for up to 10 years post intervention for particular endpoints

10 years

What Are the Treatments Tested in This Trial?

Interventions

  • Mitral valve repair
  • TEER
Trial Overview The PRIMARY trial compares two treatments for mitral valve prolapse: a less invasive procedure called transcatheter edge-to-edge repair (TEER) versus traditional surgery. Participants will be randomly assigned to one of the two options in equal numbers at multiple centers internationally.
How Is the Trial Designed?
2Treatment groups
Active Control
Group I: Surgical mitral valve repairActive Control1 Intervention
Group II: Transcatheter edge-to-edge repairActive Control1 Intervention

Mitral valve repair is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as MitraClip for:
🇪🇺
Approved in European Union as MitraClip for:
🇨🇦
Approved in Canada as MitraClip for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Annetine Gelijns

Lead Sponsor

Trials
3
Recruited
870+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Published Research Related to This Trial

In a study of 124 patients with significant mitral regurgitation, the PASCAL transcatheter valve repair system showed a 75% survival rate and a 73% rate of freedom from heart failure hospitalization after 3 years, indicating its long-term efficacy.
The procedure successfully reduced mitral regurgitation to levels of 2+ or less in 93% of patients and improved heart function, with 89% achieving NYHA class I/II status, demonstrating both safety and effectiveness in treating this condition.
Three-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study.Spargias, K., Lim, DS., Makkar, R., et al.[2023]
In a study of 1,022 patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER), applying adapted COAPT enrollment criteria identified a group with significantly lower mortality rates compared to those who did not meet these criteria (P < 0.001).
Stratifying patients based on adapted MITRA-FR criteria showed no significant difference in all-cause mortality (P = 0.19), indicating that the COAPT criteria may better predict outcomes in this population.
Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair.Koell, B., Orban, M., Weimann, J., et al.[2022]
The OCEAN-Mitral Registry included 2,150 patients with mitral regurgitation, showing a high acute procedural success rate of 94.6% for both the second-generation (G2) and fourth-generation (G4) MitraClip systems, indicating the efficacy of transcatheter edge-to-edge repair (TEER).
The use of the G4 system resulted in shorter device and fluoroscopy times compared to the G2 system, suggesting potential improvements in procedural efficiency as experience with the G4 system increases.
Short-Term Outcomes Following Transcatheter Edge-to-Edge Repair: Insights From the OCEAN-Mitral Registry.Saji, M., Yamamoto, M., Kubo, S., et al.[2023]

Citations

Three-year outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. [2023]
Outcomes Stratified by Adapted Inclusion Criteria After Mitral Edge-to-Edge Repair. [2022]
Short-Term Outcomes Following Transcatheter Edge-to-Edge Repair: Insights From the OCEAN-Mitral Registry. [2023]
Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling. [2022]
Surgical Removal of a Detached Mitral Valve Repair Clip to Resolve Cardiogenic Shock. [2022]
Mitral Surgery After Transcatheter Edge-to-Edge Repair: Society of Thoracic Surgeons Database Analysis. [2022]
Transcatheter edge-to-edge mitral valve repair in patients with acute decompensated heart failure due to severe mitral regurgitation. [2023]
Mitral valve surgery after failed MitraClip-Operation for the inoperable? [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security